DO-BO

Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)

This is a repost of a popular MAP, Market Access Podcast, from January 2023. 

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 

Related

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They […]

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.  They explore why cost‑effectiveness thresholds are making market access […]

In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare system is tackling key issues in market access and health technology assessment. Discover how Australia blends international approaches and new methods being developed by Zanfina and her team like […]